- KR₩598bn
- KR₩588bn
- KR₩65bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.86 | ||
| PEG Ratio (f) | 0.23 | ||
| EPS Growth (f) | 172.82% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7 | ||
| Price to Tang. Book | 7.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.33 | ||
| EV to EBITDA | 75.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.26% | ||
| Return on Equity | 7.59% | ||
| Operating Margin | 7.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 37,752.05 | 51,811.62 | 60,181.81 | 56,227.38 | 64,851.3 | 133,900 | 206,100 | 14.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +35.28 | +69.38 | +10.36 | -78.6 | +162.23 | +440 | +66.61 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmicell Co., Ltd. is a Korea-based company principally engaged in the biopharmaceutical business. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. It also provides steam cell storage services, and mesenchymal stem cells (MSCs) used for research areas and others. In addition, the Company engages in the fashion business, which provides women’s and men’s apparels under the brand names of Religion and Day. On March 31, 2013, the Company merged with its wholly owned subsidiary, mainly engaged in the manufacture and sale of medicines.
Directors
- Hyeon Su Kim CEO (54)
- Wun Seong Baek MDR (50)
- Si Yeong Jang MDR (51)
- Yong Man Kim MDR (47)
- Bok Gi Kim OTH
- Byeong Mu Yu DRC (49)
- Gyeong Ho Lee NID (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 20th, 1968
- Public Since
- May 20th, 1988
- No. of Shareholders
- 56,582
- No. of Employees
- 145
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 60,004,014
- Address
- 12F, Cheongho Bldg., SEOUL, 06017
- Web
- http://www.pharmicell.com/
- Phone
- +82 234960114
- Auditors
- Samil Accounting Corporation
Upcoming Events for 005690
Q2 2025 Pharmicell Co Ltd Earnings Release
Similar to 005690
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Pharmicell Co share price?
As of Today at 22:38 UTC, shares in Pharmicell Co are trading at KR₩10,080. This share price information is delayed by 15 minutes.
How has the Pharmicell Co share price performed this year?
Shares in Pharmicell Co last closed at KR₩10,080 and the price had moved by +74.09% over the past 365 days. In terms of relative price strength the Pharmicell Co share price has outperformed the FTSE Developed Asia Pacific Index by +76.08% over the past year.
What are the analyst and broker recommendations for Pharmicell Co?
The overall consensus recommendation for Pharmicell Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pharmicell Co dividend yield?
The Pharmicell Co dividend yield is 0.2% based on the trailing twelve month period.
Does Pharmicell Co pay a dividend?
Last year, Pharmicell Co paid a total dividend of KR₩20, and it currently has a trailing dividend yield of 0.2%. We do not have any data on when Pharmicell Co is to next pay dividends.
When does Pharmicell Co next pay dividends?
We do not have data on when Pharmicell Co is to next pay dividends. The historic dividend yield on Pharmicell Co shares is currently 0.2%.
How do I buy Pharmicell Co shares?
To buy shares in Pharmicell Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmicell Co?
As of the previous close price of KR₩10,080, shares in Pharmicell Co had a market capitalisation of KR₩598bn.
Where are Pharmicell Co shares listed?
Here are the trading details for Pharmicell Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 005690
What kind of share is Pharmicell Co?
Based on an overall assessment of its quality, value and momentum Pharmicell Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmicell Co share price forecast for 2025?
The analyst consensus target price for shares in Pharmicell Co is KR₩16,682. That is 65.5% above the last closing price of KR₩10,080.
Analysts covering Pharmicell Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩560 for the next financial year.
Find out moreWhat is the trend in the Pharmicell Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmicell Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +117.76%.
As of the last closing price of KR₩10,080, shares in Pharmicell Co were trading +38.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmicell Co PE Ratio?
The Pharmicell Co PE ratio based on its reported earnings over the past 12 months is 14.86. The shares last closed at KR₩10,080.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmicell Co?
Pharmicell Co's management team is headed by:
- Hyeon Su Kim - CEO
- Wun Seong Baek - MDR
- Si Yeong Jang - MDR
- Yong Man Kim - MDR
- Bok Gi Kim - OTH
- Byeong Mu Yu - DRC
- Gyeong Ho Lee - NID